ELVN · Enliven Therapeutics, Inc. · Documents
$41.52
-0.41 (-0.98%)
At close · Oct 23
Return incl. dividend (before tax)
Market Cap
$3.04B
Shares
73.27M
Volume · Oct 23
2.3M
Avg daily vol (3M)
1.27M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Effective October 14, 2026, Enliven Therapeutics appointed Kristine Ball as a Class II director and Audit Committee member, expanding its board from seven to eight; Ball’s term expires at the 2028 annual meeting. Enliven plans to initiate relcobatinib’s pivotal Phase 3 trial before year-end 2026. | 2026-10-14 | — | |
| 10-Q | — | 2026-08-05 | 2026-06-30 | |
| 8-K | — | 2026-08-05 | — | |
| 8-K | — | 2026-06-12 | 2026-06-11 | |
| 8-K | — | 2026-06-11 | — | |
| 8-K | — | 2026-06-10 | 2026-06-09 | |
| Investor Event Transcript | — | 2026-06-04 | 2026-06-30 | |
| 8-K | — | 2026-05-07 | — | |
| 10-Q | — | 2026-05-07 | 2026-03-31 | |
| DEF 14A | — | 2026-04-27 | 2026-06-09 | |
| ARS | — | 2026-04-27 | 2025-12-31 | |
| DEFA14A | — | 2026-04-27 | — | |
| PRE 14A | — | 2026-04-15 | 2026-06-09 | |
| 10-K | — | 2026-03-03 | 2025-12-31 | |
| 8-K | — | 2026-03-03 | — | |
| 8-K | — | 2026-01-07 | 2026-01-06 | |
| 8-K | — | 2025-12-11 | 2025-12-09 | |
| 8-K/A | — | 2025-11-13 | 2025-11-12 | |
| 8-K | — | 2025-11-12 | — | |
| 10-Q | — | 2025-11-12 | 2025-09-30 | |
| 10-Q | — | 2025-08-13 | 2025-06-30 | |
| S-3ASR | — | 2025-08-13 | — | |
| 8-K | — | 2025-08-13 | — | |
| 8-K | — | 2025-06-25 | 2025-06-24 | |
| 8-K | — | 2025-06-16 | 2025-06-13 | |
| 8-K | — | 2025-06-13 | — | |
| 10-Q | — | 2025-05-14 | 2025-03-31 | |
| 8-K | — | 2025-05-14 | — | |
| DEFA14A | — | 2025-04-28 | — | |
| DEF 14A | — | 2025-04-28 | 2025-06-24 | |
| ARS | — | 2025-04-28 | 2024-12-31 | |
| 8-K | — | 2025-03-13 | — | |
| 10-K | — | 2025-03-13 | 2024-12-31 | |
| 8-K | — | 2024-11-13 | — | |
| 10-Q | — | 2024-11-13 | 2024-09-30 | |
| 8-K | — | 2024-08-13 | — | |
| 10-Q | — | 2024-08-13 | 2024-06-30 | |
| 8-K | — | 2024-06-18 | — | |
| 8-K/A | — | 2024-05-29 | 2024-04-08 | |
| 8-K | — | 2024-05-14 | — | |
| 10-Q | — | 2024-05-14 | 2024-03-31 | |
| ARS | — | 2024-04-26 | 2023-12-31 | |
| DEFA14A | — | 2024-04-26 | — | |
| DEF 14A | — | 2024-04-26 | 2024-06-18 | |
| S-3 | — | 2024-04-18 | — | |
| PRE 14A | — | 2024-04-15 | 2024-06-18 | |
| 8-K | — | 2024-04-11 | — | |
| 8-K | — | 2024-04-09 | 2024-04-08 | |
| 8-K | — | 2024-03-19 | — | |
| 8-K | — | 2024-03-14 | — |
Showing 1–50 of 119 filings
Key facts
CIK
1672619
CUSIP
29337E102
13F (30d)
14 filings
14 filers
Visit website
Investor relations